Equity Overview
Price & Market Data
Price: $0.99
Daily Change: $0.00 / 0.00%
Range: $0 - $0
Market Cap: $1,811,828,352
Volume: 0
Performance Metrics
1 Week: 24.41%
1 Month: -1.96%
3 Months: -41.75%
6 Months: -47.05%
1 Year: -63.60%
YTD: -41.41%
Company Details
Employees: 204
Sector: Health technology
Industry: Biotechnology
Country: United States
Details
ProKidney Corp., a clinical-stage biotechnology company, develops a cell therapy platform for the treatment of multiple chronic kidney diseases in the United States. Its lead product candidate, rilparencel, includes autologous selected renal cells (SRC) in Phase 3 and Phase 2 clinical studies in subjects with moderate to severe chronic kidney disease and diabetes. The company also develops a cryopreserved version of rilparencel that allows for long-term product preservation to be used in Phase 2 and 3 trials of rilparencel. ProKidney Corp. was founded in 2015 and is headquartered in Winston-Salem, North Carolina.